Spots Global Cancer Trial Database for urogenital neoplasm
Every month we try and update this database with for urogenital neoplasm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer | NCT01540994 | Prostatic Neopl... | radiation thera... | 50 Years - 90 Years | Sharp HealthCare | |
| Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. | NCT01310894 | Prostate Cancer | TOOKAD® Soluble | 18 Years - | Steba Biotech S.A. | |
| Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. | NCT01310894 | Prostate Cancer | TOOKAD® Soluble | 18 Years - | Steba Biotech S.A. | |
| [Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer | NCT06229366 | Prostate Cancer Metastatic Cast... Biochemically R... | [Ac-225]-PSMA-6... [Ac-225]-PSMA-6... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer | NCT01540994 | Prostatic Neopl... | radiation thera... | 50 Years - 90 Years | Sharp HealthCare | |
| [Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer | NCT06229366 | Prostate Cancer Metastatic Cast... Biochemically R... | [Ac-225]-PSMA-6... [Ac-225]-PSMA-6... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer | NCT04225299 | Localized Prost... | TOOKAD® | 18 Years - | Steba Biotech S.A. | |
| Study Using WST11 in Patients With Localized Prostate Cancer | NCT00975429 | Prostate Cancer | WST11 WST11 | 18 Years - | Steba Biotech S.A. | |
| JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin | NCT01599013 | Bladder Transit... | Vinflunine, Gem... Vinflunine, Car... | 18 Years - 79 Years | Pierre Fabre Medicament | |
| Study of WST11 in Patients With Localized Prostate Cancer | NCT00707356 | Prostate Cancer | WST11 | 18 Years - | Steba Biotech S.A. | |
| JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin | NCT01599013 | Bladder Transit... | Vinflunine, Gem... Vinflunine, Car... | 18 Years - 79 Years | Pierre Fabre Medicament | |
| Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer | NCT01875393 | Prostate Cancer | TOOKAD® Soluble | 18 Years - | Steba Biotech S.A. | |
| 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients | NCT02602067 | Breast Neoplasm Head and Neck N... Skin Neoplasm Respiratory Tra... Urogenital Neop... Digestive Syste... Pancreatic Neop... Connective and ... Lymphoma, Non-H... | 131I-Tenatumoma... | 18 Years - 75 Years | sigma-tau i.f.r. S.p.A. | |
| Study Using WST11 in Patients With Localized Prostate Cancer | NCT00975429 | Prostate Cancer | WST11 WST11 | 18 Years - | Steba Biotech S.A. | |
| Study Using WST11 in Patients With Localized Prostate Cancer | NCT00975429 | Prostate Cancer | WST11 WST11 | 18 Years - | Steba Biotech S.A. | |
| 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients | NCT02602067 | Breast Neoplasm Head and Neck N... Skin Neoplasm Respiratory Tra... Urogenital Neop... Digestive Syste... Pancreatic Neop... Connective and ... Lymphoma, Non-H... | 131I-Tenatumoma... | 18 Years - 75 Years | sigma-tau i.f.r. S.p.A. | |
| Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer | NCT00946881 | Prostate Cancer | WST 11 -mediate... | 18 Years - | Steba Biotech S.A. | |
| Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer | NCT00946881 | Prostate Cancer | WST 11 -mediate... | 18 Years - | Steba Biotech S.A. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
